ArticlePloS one2026
Immunoinformatics-driven design of multi-epitope vaccine targeting antibiotic-resistant Salmonella typhimurium.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Recent developments in typhoidal and non-typhoidal Salmonella vaccines.Current opinion in infectious diseases · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Salmonella typhimurium, a Gram-negative bacterium, is a significant cause of gastroenteritis worldwide, with outbreaks occurring in diverse regions. Despite its global impact, there is currently no vaccine for human use against this pathogen. Complicating treatment efforts, S. typhimurium has exhibited resistance to multiple antibiotics, posing challenges to effectively managing infections. Given its prevalence and unresolved antibiotic resistance-associated global health burden, urgent attention is required to develop a genuinely effective vaccine. Using the S. typhimurium complete proteome data, vaccinomics-assisted immunoinformatics techniques were employed in the current investigation to find possible vaccine candidates. Candidate proteins were identified based on essentiality, lack of homology with the human proteome, and absence from the gut microbiome. Using a reverse vaccinology methodology, four antigenic outer membrane proteins were ranked in order of priority for lead epitope prediction. To boost immune responses against the intended vaccination, lead B and T-cell epitopes were coupled with appropriate linker and adjuvant peptide sequences to create multiepitope-based chimeric vaccines. The ST-MEVC construct was ranked according to several immunological, physicochemical, and immune receptor docking scores. Immune simulation predicted a strong immunogenic response for the proposed vaccine formulation. Molecular dynamics simulations analysis confirmed stable molecular interactions between the primary vaccine construct and the host receptors. The ST-MEVC construct's feasible cloning potential within the E. coli expression system was anticipated by in silico restriction and cloning studies. The proposed vaccine design is expected to elicit more robust immune responses against S. typhimurium infections and will be safer, more efficacious, and more promising for investigation using in vitro/in vivo assays.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.